Cargando…

A precision medicine classification for treatment of acute myeloid leukemia in older patients

BACKGROUND: Older patients (≥ 60 years) with acute myeloid leukemia (AML) often have multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are associated with poor outcome. Beat AML is a Leukemia and Lymphoma Society-sponsored, multicenter umbrella study that algorithmical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mims, Alice S., Kohlschmidt, Jessica, Borate, Uma, Blachly, James S., Orwick, Shelley, Eisfeld, Ann-Kathrin, Papaioannou, Dimitrios, Nicolet, Deedra, Mrόzek, Krzysztof, Stein, Eytan, Bhatnagar, Bhavana, Stone, Richard M., Kolitz, Jonathan E., Wang, Eunice S., Powell, Bayard L., Burd, Amy, Levine, Ross L., Druker, Brian J., Bloomfield, Clara D., Byrd, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220739/ https://www.ncbi.nlm.nih.gov/pubmed/34162404 http://dx.doi.org/10.1186/s13045-021-01110-5

Ejemplares similares

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
por: Eisfeld, Ann-Kathrin, et al.
Publicado: (2018)

Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
por: Bhatnagar, Bhavana, et al.
Publicado: (2023)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
por: Mrózek, Krzysztof, et al.
Publicado: (2019)

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023)

Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia
por: Papaioannou, Dimitrios, et al.
Publicado: (2017)

Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement
por: Bill, Marius, et al.
Publicado: (2021)

Association of social deprivation with survival in younger adult patients with AML: an Alliance study
por: Rebechi, Melanie, et al.
Publicado: (2023)

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
por: Eisfeld, A-K, et al.
Publicado: (2017)

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia
por: Bill, Marius, et al.
Publicado: (2020)

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML
por: Larkin, Karilyn T., et al.
Publicado: (2022)

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA
por: Walker, Christopher J., et al.
Publicado: (2018)

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq
por: Saygin, Caner, et al.
Publicado: (2021)

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia
por: Papaioannou, Dimitrios, et al.
Publicado: (2021)

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
por: Mims, Alice, et al.
Publicado: (2023)

Controlled variable selection in Weibull mixture cure models for high‐dimensional data
por: Fu, Han, et al.
Publicado: (2022)

Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system
por: Byrd, John C., et al.
Publicado: (2023)

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
por: Whitman, Susan P., et al.
Publicado: (2013)

Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial
por: Rosenberg, Len, et al.
Publicado: (2021)

MuCor: mutation aggregation and correlation
por: Kroll, Karl W., et al.
Publicado: (2016)

No evidence for microsatellite instability in acute myeloid leukemia
por: Walker, Christopher J., et al.
Publicado: (2017)

A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Saygin, Caner, et al.
Publicado: (2020)

Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts
por: Gregory, Thomas, et al.
Publicado: (2020)

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia
por: Ngankeu, Apollinaire, et al.
Publicado: (2017)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
por: Niederwieser, Christian, et al.
Publicado: (2014)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485
por: Mims, Alice S., et al.
Publicado: (2018)

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories
por: Borate, Uma, et al.
Publicado: (2023)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503)
por: Blum, William, et al.
Publicado: (2016)

TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020)

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia
por: Giacopelli, Brian, et al.
Publicado: (2021)

Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia
por: Underwood, Brynne, et al.
Publicado: (2020)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
por: Saliba, Antoine N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rs9t9qvm6ii7553ckq7mh3bg7s